Cure8 research brief
Sarcopenia (loss of muscle mass/strength) was common among hospitalized adults with active UC and linked to inflammation, changes in blood metabolites (bile acids, acylcarnitines), and shifts in the gut microbiome.
These connections point to nutrition, inflammation control, and gut health as relevant to muscle outcomes in UC.
Adults with ulcerative colitis, gastroenterologists and IBD care teams, researchers studying IBD-related malnutrition or the gut microbiome, dietitians/nutritionists working with IBD patients.
This study examined hospitalized adults with active ulcerative colitis (UC) and age-matched healthy controls to characterize sarcopenia (low muscle mass and strength) and its links with blood metabolites and the gut microbiome.
Sarcopenia was common in the UC group and was associated with higher systemic inflammation (hsCRP), changes in circulating bile acids and acylcarnitines, and shifts in gut bacteria (lower Bacteroides, higher Streptococcus). Metagenomic analysis also suggested reduced protein digestion/absorption pathways in sarcopenic UC patients.
The report is based on the authors’ abstract and summary data from a single-center cohort (57 UC patients, 35 controls). The findings describe associations, not proven cause-and-effect; the authors adjusted some analyses for disease activity and inflammation, and some associations (hippuric acid) lost significance after adjustment.
If you have UC and are concerned about muscle loss, this study highlights that inflammation, diet/nutrition, and the gut microbiome may all be related to muscle health. Talk with your clinical team about screening for sarcopenia (muscle strength and body-composition testing), assessing nutrition, and managing active inflammation.
Findings come from a single-center observational cohort and show associations, not causation. Some metabolite associations were attenuated after adjusting for disease activity and inflammation. The brief is grounded in the article abstract and summary provided by the journal.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
GLP-1 receptor agonists — drugs commonly used to treat obesity and metabolic disease — may help patients with IBD by reducing visceral fat and improving cardiometabolic health.
If you have PSC-IBD or care for someone who does, this study suggests the gut microbiota and its ability to make secondary bile acids may help drive inflammation and colorectal dysplasia risk.
